Benjamin Ortiz
Research Subjects
Research Interests
Benjamin Ortiz has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Stanley J. Szefler
Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado; Pediatric Asthma Research Program, The Breathing Institute, Children's Hospital Colorado, Aurora, Colorado
4 shared publications - Nadia Daizadeh
Advanced Quantitative Sciences Novartis Pharmaceuticals Corporation East Hanover New Jersey USA
3 shared publications Tmirah Haselkorn
EpiMetrix, Inc., Los Altos, CA
3 shared publications- Abhishek Kavati
Novartis Pharmaceuticals Corporation, East Hanover, NJ
2 shared publications Ahmar Iqbal
Genentech, Inc., South San Francisco, CA
2 shared publications- Alberto Papi
University of Ferrara, S. Anna University Hospital, Ferrara, Italy
2 shared publications
Latest Publications
Efficacy and Safety of Ligelizumab in Individuals With Confirmed Peanut Allergy
Background: The growing burden of food allergy globally has been accompanied by increasing demand for effective treatments. Ligelizumab is a humanised anti–IgE monoclonal antibody that can strongly inhibit allergic pathways. This phase 3 study evaluated the efficacy and safety of ligelizumab in participants with confirmed IgE‐mediated peanut allergy. Methods: This was a 52‐week, multicentre, randomised, double‐blind, placebo‐controlled study in adults and adolescents with confirmed peanut allergy. Participants received either ligelizumab 120 mg or 240 mg or placebo subcutaneously every 4 weeks. The primary endpoint was the proportion of participants tolerating ≥ 600 mg of peanut protein without dose‐limiting symptoms during a double‐blind, placebo‐controlled, food challenge at week 12. Secondary endpoints included tolerance to higher doses of peanut protein. However, the study was terminated early due to evidence from blinded data reviews that the target efficacy would not be met. All participants enrolled at the time of termination could complete week 12 assessments. Results: The primary endpoint was met in the ligelizumab 240 mg treatment arm, with 44.7% (21/47) of participants tolerating ≥ 600 mg of peanut protein versus 4.3% (1/23) for placebo. Numerically higher efficacy was observed in the ligelizumab 120 mg treatment arm (15.7% [8/51]) versus placebo. Positive dose‐dependent trends were observed across the key secondary endpoints, but statistical significance, per the pre‐planned testing strategy, was not achieved. Safety profiles were consistent with known data, with no new safety signals observed. Conclusions: Ligelizumab 240 mg demonstrated clinical superiority over placebo, with favourable tolerability, in treating IgE‐mediated peanut allergy, despite early termination of the study.
Efficacy and Safety of Ligelizumab in Individuals With Confirmed Peanut Allergy
Background: The growing burden of food allergy globally has been accompanied by increasing demand for effective treatments. Ligelizumab is a humanised anti–IgE monoclonal antibody that can strongly inhibit allergic pathways. This phase 3 study evaluated the efficacy and safety of ligelizumab in participants with confirmed IgE‐mediated peanut allergy. Methods: This was a 52‐week, multicentre, randomised, double‐blind, placebo‐controlled study in adults and adolescents with confirmed peanut allergy. Participants received either ligelizumab 120 mg or 240 mg or placebo subcutaneously every 4 weeks. The primary endpoint was the proportion of participants tolerating ≥ 600 mg of peanut protein without dose‐limiting symptoms during a double‐blind, placebo‐controlled, food challenge at week 12. Secondary endpoints included tolerance to higher doses of peanut protein. However, the study was terminated early due to evidence from blinded data reviews that the target efficacy would not be met. All participants enrolled at the time of termination could complete week 12 assessments. Results: The primary endpoint was met in the ligelizumab 240 mg treatment arm, with 44.7% (21/47) of participants tolerating ≥ 600 mg of peanut protein versus 4.3% (1/23) for placebo. Numerically higher efficacy was observed in the ligelizumab 120 mg treatment arm (15.7% [8/51]) versus placebo. Positive dose‐dependent trends were observed across the key secondary endpoints, but statistical significance, per the pre‐planned testing strategy, was not achieved. Safety profiles were consistent with known data, with no new safety signals observed. Conclusions: Ligelizumab 240 mg demonstrated clinical superiority over placebo, with favourable tolerability, in treating IgE‐mediated peanut allergy, despite early termination of the study.
- Open Access
- 11 August 2022
- Published by Elsevier in Respiratory Medicine
- Vol. 202, 106938
Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline
- 11 August 2022
- Published by Elsevier in Respiratory Medicine
- Vol. 202, 106938
Open AccessDupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline
- Open Access
- 11 October 2021
- Published by BMJ
- Vol. 106 (Suppl 2) , A70
166 Efficacy of Dupilumab in Children With Uncontrolled, Moderate-to-Severe Type 2 Asthma, With and Without Evidence of Allergy Enrolled in Phase 3 VOYAGE
The allergic phenotype is an important subset of asthma patients with type 2 inflammation. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4/IL-13, key and central drivers of type 2 inflammation in multiple diseases. In phase 3 VOYAGE, add-on dupilumab 100mg/200mg (body weight ≤30kg/>30kg, respectively) every 2 weeks vs placebo, reduced severe asthma exacerbations by 59.3% (P<0.0001) and improved lung function in children aged 6 to <12 years with uncontrolled moderate-to-severe type 2 asthma (baseline blood eosinophils ≥150cells/µl or FeNO ≥20ppb). This analysis evaluated the efficacy of dupilumab in pediatric patients with type 2 asthma with/without evidence of allergic asthma (total serum IgE ≥30IU/mL and ≥1 perennial aeroallergen-specific IgE ≥0.35kU/L at baseline). Annualized severe exacerbation rate during the 52-week treatment period was assessed using a negative binomial model. 350 pediatric patients with type 2 asthma were enrolled: of which, 261 had evidence of allergic asthma and 89 did not. Baseline characteristics were similar between subgroups, except for prevalence of ongoing atopic comorbidities (99.6% vs 77.5%) and median levels of type 2 biomarkers (blood eosinophils: 540.00cells/µL vs 310.00cells/µL; FeNO: 28ppb vs 13ppb; total serum IgE: 657.00IU/mL vs 107.00IU/mL) which were all higher in patients with vs without evidence of allergic asthma. Dupilumab vs placebo significantly reduced annualized severe exacerbation rate by 62% (P<0.0001) in patients with, and 51% (P<0.05) in patients without evidence of allergic asthma. No significant interaction was observed between the treatment effect and evidence of allergic asthma. In the overall safety population, the incidence of treatment-emergent adverse events (TEAEs) was similar across treatment groups; the most common TEAE occurring more frequently in the dupilumab group was injection site erythema (12.9% dupilumab vs 9.7% placebo). The majority of pediatric type 2 asthma patients enrolled in VOYAGE had evidence of allergic asthma; these patients had very high levels of type 2 biomarkers. Dupilumab demonstrated efficacy in reducing severe asthma exacerbations in children aged 6 to <12 years with uncontrolled, moderate-to-severe type 2 asthma, with or without evidence of allergic asthma.
- 11 October 2021
- Published by BMJ
- Vol. 106 (Suppl 2) , A70
Open Access166 Efficacy of Dupilumab in Children With Uncontrolled, Moderate-to-Severe Type 2 Asthma, With and Without Evidence of Allergy Enrolled in Phase 3 VOYAGE
The allergic phenotype is an important subset of asthma patients with type 2 inflammation. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4/IL-13, key and central drivers of type 2 inflammation in multiple diseases. In phase 3 VOYAGE, add-on dupilumab 100mg/200mg (body weight ≤30kg/>30kg, respectively) every 2 weeks vs placebo, reduced severe asthma exacerbations by 59.3% (P<0.0001) and improved lung function in children aged 6 to <12 years with uncontrolled moderate-to-severe type 2 asthma (baseline blood eosinophils ≥150cells/µl or FeNO ≥20ppb). This analysis evaluated the efficacy of dupilumab in pediatric patients with type 2 asthma with/without evidence of allergic asthma (total serum IgE ≥30IU/mL and ≥1 perennial aeroallergen-specific IgE ≥0.35kU/L at baseline). Annualized severe exacerbation rate during the 52-week treatment period was assessed using a negative binomial model. 350 pediatric patients with type 2 asthma were enrolled: of which, 261 had evidence of allergic asthma and 89 did not. Baseline characteristics were similar between subgroups, except for prevalence of ongoing atopic comorbidities (99.6% vs 77.5%) and median levels of type 2 biomarkers (blood eosinophils: 540.00cells/µL vs 310.00cells/µL; FeNO: 28ppb vs 13ppb; total serum IgE: 657.00IU/mL vs 107.00IU/mL) which were all higher in patients with vs without evidence of allergic asthma. Dupilumab vs placebo significantly reduced annualized severe exacerbation rate by 62% (P<0.0001) in patients with, and 51% (P<0.05) in patients without evidence of allergic asthma. No significant interaction was observed between the treatment effect and evidence of allergic asthma. In the overall safety population, the incidence of treatment-emergent adverse events (TEAEs) was similar across treatment groups; the most common TEAE occurring more frequently in the dupilumab group was injection site erythema (12.9% dupilumab vs 9.7% placebo). The majority of pediatric type 2 asthma patients enrolled in VOYAGE had evidence of allergic asthma; these patients had very high levels of type 2 biomarkers. Dupilumab demonstrated efficacy in reducing severe asthma exacerbations in children aged 6 to <12 years with uncontrolled, moderate-to-severe type 2 asthma, with or without evidence of allergic asthma.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA880
Effect of dupilumab on improving physical activity in patients with severe asthma
Background: The Asthma Quality of Life Questionnaire (AQLQ) includes items assessing the impact of asthma on physical activity. Dupilumab (DPL), a fully human mAb, blocks the shared receptor component of IL-4/IL-13, key and central drivers of type 2 inflammation in multiple diseases. In phase 3 VENTURE (NCT02528214), DPL 300mg every 2 weeks (q2w) vs placebo (PBO) reduced oral corticosteroid (OCS) maintenance dose and rate of severe asthma exacerbations and improved pre-bronchodilator FEV1 independently of baseline eosinophil levels as well as health-related quality of life (QoL) in patients (pts) with OCS-dependent, severe asthma. DPL was generally well tolerated. Aim: To assess the effect of DPL on physical activity. Methods: Physical activity-related items on the AQLQ assess the impact of asthma on activity on a scale of 1–7; scores of 6/7 indicate little/no limitation in performing physical activities. The proportion of pts with scores of 6/7 on the 4 physical activity-related AQLQ items (#1, #2, #4, #31) was evaluated at baseline (BL), Week (Wk) 12, and Wk24. Results: Proportion of pts with scores of 6/7 on physical activity-related items was comparable at BL in both groups. DPL pts continuously improved over time, with more DPL vs PBO pts scoring 6/7 at Wk24 (odds ratio 1.92–2.70; all p<0.05; Figure). Conclusion: DPL improved physical activity-related QoL while reducing OCS dose in pts with OCS-dependent, severe asthma.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA880
Effect of dupilumab on improving physical activity in patients with severe asthma
Background: The Asthma Quality of Life Questionnaire (AQLQ) includes items assessing the impact of asthma on physical activity. Dupilumab (DPL), a fully human mAb, blocks the shared receptor component of IL-4/IL-13, key and central drivers of type 2 inflammation in multiple diseases. In phase 3 VENTURE (NCT02528214), DPL 300mg every 2 weeks (q2w) vs placebo (PBO) reduced oral corticosteroid (OCS) maintenance dose and rate of severe asthma exacerbations and improved pre-bronchodilator FEV1 independently of baseline eosinophil levels as well as health-related quality of life (QoL) in patients (pts) with OCS-dependent, severe asthma. DPL was generally well tolerated. Aim: To assess the effect of DPL on physical activity. Methods: Physical activity-related items on the AQLQ assess the impact of asthma on activity on a scale of 1–7; scores of 6/7 indicate little/no limitation in performing physical activities. The proportion of pts with scores of 6/7 on the 4 physical activity-related AQLQ items (#1, #2, #4, #31) was evaluated at baseline (BL), Week (Wk) 12, and Wk24. Results: Proportion of pts with scores of 6/7 on physical activity-related items was comparable at BL in both groups. DPL pts continuously improved over time, with more DPL vs PBO pts scoring 6/7 at Wk24 (odds ratio 1.92–2.70; all p<0.05; Figure). Conclusion: DPL improved physical activity-related QoL while reducing OCS dose in pts with OCS-dependent, severe asthma.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64) , 4613
Late Breaking Abstract - Dupilumab long-term safety and efficacy in patients with asthma: LIBERTY ASTHMA TRAVERSE
Introduction: Dupilumab (DPL), a fully human mAb, blocks the shared receptor component for IL‑4/IL‑13. The efficacy and safety of DPL in asthma have been demonstrated up to 52 wks in phase (P) 2/3 studies. Aim: This open-label extension (OLE) study (NCT02134028) assessed long-term safety and efficacy of DPL in adult and adolescent patients (pts) who had completed a DPL asthma study (P2b DRI, P2 EXPEDITION, P3 QUEST or VENTURE). Methods: 2282 moderate-to-severe asthma or OCS-dependent severe asthma pts received add‑on SC DPL 300mg every 2 wks up to 96 wks. Treatment-emergent adverse events (TEAE), annualized rate of severe asthma exacerbations (AER) during the treatment period, and change from parent study baseline (BL) in FEV1 and biomarkers up to Wk 96 were assessed. Results: 2039 pts completed the OLE treatment period with a safety profile that was consistent with the shorter-duration parent studies (Table). The low unadjusted AER and improvement in FEV1 observed in the parent studies were sustained during the OLE. Similar efficacy was seen in pts with elevated type 2 biomarkers from DRI/QUEST. By Wk 96, blood eosinophils decreased to below-parent study BL levels in pts from DRI/QUEST and were near-parent study BL levels in pts from VENTURE; total IgE levels decreased by 82% (median % change from parent BL). Conclusion: Long-term use of dupilumab was well tolerated and showed sustained efficacy in asthma pts up to 96 wks.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64) , 4613
Late Breaking Abstract - Dupilumab long-term safety and efficacy in patients with asthma: LIBERTY ASTHMA TRAVERSE
Introduction: Dupilumab (DPL), a fully human mAb, blocks the shared receptor component for IL‑4/IL‑13. The efficacy and safety of DPL in asthma have been demonstrated up to 52 wks in phase (P) 2/3 studies. Aim: This open-label extension (OLE) study (NCT02134028) assessed long-term safety and efficacy of DPL in adult and adolescent patients (pts) who had completed a DPL asthma study (P2b DRI, P2 EXPEDITION, P3 QUEST or VENTURE). Methods: 2282 moderate-to-severe asthma or OCS-dependent severe asthma pts received add‑on SC DPL 300mg every 2 wks up to 96 wks. Treatment-emergent adverse events (TEAE), annualized rate of severe asthma exacerbations (AER) during the treatment period, and change from parent study baseline (BL) in FEV1 and biomarkers up to Wk 96 were assessed. Results: 2039 pts completed the OLE treatment period with a safety profile that was consistent with the shorter-duration parent studies (Table). The low unadjusted AER and improvement in FEV1 observed in the parent studies were sustained during the OLE. Similar efficacy was seen in pts with elevated type 2 biomarkers from DRI/QUEST. By Wk 96, blood eosinophils decreased to below-parent study BL levels in pts from DRI/QUEST and were near-parent study BL levels in pts from VENTURE; total IgE levels decreased by 82% (median % change from parent BL). Conclusion: Long-term use of dupilumab was well tolerated and showed sustained efficacy in asthma pts up to 96 wks.
- Open Access
- 1 February 2020
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (2) , 507-515.e10
Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population
- 1 February 2020
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (2) , 507-515.e10
Open AccessOmalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population
- Open Access
- 14 February 2019
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 15 (5) , 553-569
Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018
Introduction: Omalizumab is a recombinant monoclonal anti-IgE antibody approved in the US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma [SAA] in Europe). A 2016 review of 24 real-world effectiveness studies in SAA published between 2008–2015 concluded that omalizumab was associated with significant improvements in objective and subjective outcomes with benefits extending beyond 2 years. Several new real-world studies have been published since, bringing the total to 42 studies. Areas covered: This systematic review of 42 studies published since 2008 updates and extends the 2016 review on the real-word evidence on omalizumab in SAA. It offers greater granularity as to time windows within which outcomes are reported and includes studies extending well beyond 4 years post omalizumab initiation. Expert commentary: This review firmly establishes the short-term effectiveness of omalizumab in adolescent and adult patients with SAA at 1 year, and provides strong evidence of long-term effectiveness up to 4 years and emergent evidence of effectiveness beyond 4 years. In the aggregate, these 42 studies underscore the long-term effectiveness of omalizumab in terms of: reducing exacerbations and symptoms, achieving asthma control, improving lung function, enhancing quality of life, decreasing emergency department visits and hospitalizations, and promoting concomitant medication-sparing.
- 14 February 2019
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 15 (5) , 553-569
Open AccessShort- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018
Introduction: Omalizumab is a recombinant monoclonal anti-IgE antibody approved in the US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma [SAA] in Europe). A 2016 review of 24 real-world effectiveness studies in SAA published between 2008–2015 concluded that omalizumab was associated with significant improvements in objective and subjective outcomes with benefits extending beyond 2 years. Several new real-world studies have been published since, bringing the total to 42 studies. Areas covered: This systematic review of 42 studies published since 2008 updates and extends the 2016 review on the real-word evidence on omalizumab in SAA. It offers greater granularity as to time windows within which outcomes are reported and includes studies extending well beyond 4 years post omalizumab initiation. Expert commentary: This review firmly establishes the short-term effectiveness of omalizumab in adolescent and adult patients with SAA at 1 year, and provides strong evidence of long-term effectiveness up to 4 years and emergent evidence of effectiveness beyond 4 years. In the aggregate, these 42 studies underscore the long-term effectiveness of omalizumab in terms of: reducing exacerbations and symptoms, achieving asthma control, improving lung function, enhancing quality of life, decreasing emergency department visits and hospitalizations, and promoting concomitant medication-sparing.
- 1 July 2018
- Published by Elsevier in Clinical Therapeutics
- Vol. 40 (7) , 1140-1158.e4
Real-world Clinical Characteristics, Treatment Patterns, and Exacerbations in US Patients With Asthma Newly Treated With Omalizumab
- 1 July 2018
- Published by Elsevier in Clinical Therapeutics
- Vol. 40 (7) , 1140-1158.e4
Real-world Clinical Characteristics, Treatment Patterns, and Exacerbations in US Patients With Asthma Newly Treated With Omalizumab
- Open Access
- 1 February 2018
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 141 (2) , AB100
The Composite Asthma Severity Index: A Tool for Assessing Impact of Omalizumab Treatment in Children with Moderate-to-Severe Persistent Allergic Asthma
- 1 February 2018
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 141 (2) , AB100
Open AccessThe Composite Asthma Severity Index: A Tool for Assessing Impact of Omalizumab Treatment in Children with Moderate-to-Severe Persistent Allergic Asthma